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Introduction
Phagocytic leukocytes, such as neutrophils and monocyte/macrophages, are key components of the innate immune system and play an essential role in host defense. These cells utilize an array of oxygen-dependent and oxygen-independent microbicidal mechanisms to recognize, ingest, and destroy pathogens (Tosi, 2005) . These responses are modulated by a variety of extrinsic factors, including bacterial products, lipids, cytokines, and chemokines, and it is now apparent that the nature of a given inflammatory response represents interplay between pro-inflammatory and anti-inflammatory immune modulators (Serhan, 2007; Gordon, 2007) .
Among these modulators are signals that recruit phagocytes to sites of inflammation (i.e., chemoattractants), which is a critical process during immune responses to tissue injury and infection [reviewed in (Ley et al., 2007) ].
One of the most studied phagocyte chemoattractants is N-formyl-methionyl-leucylphenyalanine (fMLF), which is a prototype for microbe-derived formylated peptides (Schiffmann et al., 1975) . However, subsequent studies have shown that formylated peptides are produced by mitochondria and can be released when mitochondria are damaged during tissue injury [reviewed in . Thus, N-formyl peptides can also be considered as alarmins, which are defined as endogenous molecules that signal tissue and cell damage (Oppenheim et al., 2007) . N-formyl peptides activate phagocytes through G protein-coupled receptors known as formyl peptide receptors (FPR) (Le et al., 2002) . FPR1 was the first FPR receptor cloned and encodes a high-affinity receptor for fMLF (Boulay et al., 1990 ).
Subsequently, it was found that two additional FPR genes exist in humans, and these were originally designated as FPR-like 1 (FPRL1; 69% identity to FPR1) and FPR-like 2 (FPRL2; 56% identity to FPR1) (Ye et al., 1992; Murphy et al., 1992; Bao et al., 1992) . Recently, the MOL 60673 FPRL1 and FPRL2 are now designated as FPR2 and FPR3, respectively . FPR1 is expressed on phagocytes and a small number of non-phagocytic cells (e.g., hepatocytes, immature dendritic cells, astrocytes, microglial cells, etc.), whereas, FPR2 is expressed in an even wider variety of cell types, including phagocytic leukocytes, hepatocytes, epithelial cells, T lymphocytes, neuroblastoma cells, astrocytoma cells, and microvascular endothelial cells [reviewed in ]. These patterns of tissue expression suggest that FPR1/FPR2 may also participate in a number of functions other than host defense.
Compared to FPR1, FPR2 exhibits a high level of ligand promiscuity and is activated by numerous and chemically unrelated ligands, including synthetic peptides, pathogen-derived peptides, host-derived peptides, and lipids [reviewed in ]. In addition to natural peptides and endogenous arachidonic acid metabolites, novel synthetic peptides and several small-molecule non-peptide agonists of FPR1 and FPR2 have recently been reported (e.g., (Nanamori et al., 2004; Edwards et al., 2005; Bürli et al., 2006; Schepetkin et al., 2007; Schepetkin et al., 2008) ). Indeed, the identification development of small-molecule ligands represents an ideal approach to analyze FPR structure and function, since such small-molecules are well defined and can be easily modified for structure-activity relationship (SAR) analysis, they have advantages over peptides or proteins as potential therapeutics, and they can provide a basis for construction of useful pharmacophore models of FPR1/FPR2 agonists.
Based on the importance of FPRs in health and disease pathogenesis and the need for addition receptor-specific FPR agonists, we screened a library of 6,000 synthetic compounds to identify novel and potent agonists for FPR1 and FPR2. After further SAR analysis and analog screening, we identified 6 FPR1-specific agonists, 21 FPR2-specific agonists, and 9 mixed FPR1/FPR2 agonists with EC 50 values in the low micromolar range. Specificity of the compounds was supported using a Ca 2+ mobilization assay in HL-60 cells transfected with either (San Diego, CA), and Enamine (Kiev, Ukraine). The purity and identity of the compounds were verified using NMR spectroscopy, elemental analysis, and mass spectroscopy, as performed by the suppliers. The compounds were diluted in DMSO at a concentration of 2 mg/ml and stored at -80°C.
Cell Culture. Rat basophilic leukemia (RBL-2H3) cells transfected with human FPR1
(RBL-FPR1) or FPR2 (RBL-FPR2) were cultured in DMEM supplemented with 20% (v/v) FBS, 10 mM HEPES, 100 μ g/ml streptomycin, 100 U/ml penicillin, and G418 (250 μ g/ml), as described previously (Nanamori et al., 2004) . Human HL-60 cells stably transfected with human FPR1 (HL-60-FPR1) or FPR2 (HL-60-FPR2) were cultured in RPMI supplemented with 10%
heat inactivated fetal calf serum, 10 mM HEPES, 100 µg/ml streptomycin, 100 U/ml penicillin, and G418 (1 mg/ml), as described previously (Christophe et al., 2002) . Wild-type RBL-2H3 and HL-60 cells were cultured under the same conditions, but without G418.
Isolation of Human Neutrophils. Blood was collected from healthy donors in accordance with a protocol approved by the Institutional Review Board at Montana State University. Neutrophils were purified from the blood using dextran sedimentation, followed by MOL 60673 8 previously (Schepetkin et al., 2007 We utilized a ligand-based approach for molecular modeling based on the use of field points (Cheeseright et al., 2007) . the Extended Electron Distribution (XED) force field (Vinter, 1994; Cheeseright et al., 2007) .
This algorithm incorporated in FieldTemplater software allowed us to obtain up to 100 independent conformations, which were passed to further calculation of field points surrounding each conformation of each molecule. For the generation of field point patterns, probe atoms having positive, negative, and zero charge were placed in the vicinity of a given conformation, and energy of their interaction with the molecular field was calculated using the XED parameter set. Positions of energy extrema for positive probes give "negative" field points, while energy extrema for negative and neutral probe atoms correspond to "positive" and steric field points, respectively. Hydrophobic field points were also generated with neutral probes capable of penetrating into the molecular core and reaching extrema in the centers of hydrophobic regions, e.g. benzene rings. The size of a field point depends on magnitude of an extremum (Cheeseright et al., 2006) . There are approximately the same number of field points as heavy atoms in a 'drug-like' molecule, and the field points are colored according to the following convention: blue = electron-rich (negative); red = electron-deficient (positive); yellow = van der Waals attractive (steric); and orange = hydrophobic (Cheeseright et al., 2007) . A detailed description of the field point calculation procedure has been published elsewhere (Cheeseright et al., 2006) . This trio and quintet were regarded as templates corresponding to the unknown active sites of FPR1 and FPR2, respectively. The templates were characterized by similarity S, which is calculated as a relative index according Cheeseright et al. (Cheeseright et al., 2007) . Generating conformations, field point patterns, and building templates were performed with default options of FieldTemplater software.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Identification of FPR1/FPR2 Agonists in High-throughput Screening
In previous studies, we screened a 10,000-compound library for molecules that activated human neutrophil reactive oxygen species (ROS) production and identified 11 such compounds, including two novel FPR agonists (Schepetkin et al., 2007) . However, not all FPR agonists can activate phagocyte ROS production (Nanamori et al., 2004; Zhou et al., 2007) , and some heterocyclic compounds can scavenge ROS. Thus, we rescreened a subset of this compound library for novel FPR1/FPR2 agonists using a Ca 2+ mobilization assay. The subset of 6,000 compounds was selected from the parent library as compounds that contained at least two heterocycles separated by a chemical linker with >2 bonds, since previous studies have shown that these characteristics are almost always present in non-peptide FPR1/FPR2 agonists (Nanamori et al., 2004; Edwards et al., 2005; Bürli et al., 2006; Frohn et al., 2007; Zhou et al., 2007; Schepetkin et al., 2007; Schepetkin et al., 2008) . To distinguish between FPR1 and FPR2
agonists, we performed primary high-throughput screening for compounds that activated Ca neutrophil agonists, based on their ability to activate ROS production, although receptor specificity was not evaluated (Schepetkin et al., 2007) . Using our previous nomenclature (Schepetkin et al., 2008) , these agonists are designated here as AG-26 and AG-22. The remaining 10 compounds are designated as (AG)-09/1 through AG-09/10. Structures of the selected compounds are shown in Figure 1 , and their activities are reported in Table 1 .
Interestingly, none of these 10 agonists activated human or murine neutrophil ROS production, which explains why they were not identified in previous screens (data not shown). Specificity of these compounds was verified by analysis of their ability to activate Ca 2+ mobilization in HL-60 cells transfected with human FPR1 or FPR2 (Table 1) .
Of the selected compounds, two are FPR1-specific agonists (AG-09/1 and AG-09/2) and have a common 2-(benzimidazol-2-ylsulfanyl)-N-phenyl-acetamide scaffold. Seven compounds (AG-26 and AG-09/4 through AG-09/9) are specific for FPR2. Among these, compounds AG-09/4 and AG-09/5 have a common N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide scaffold.
Compounds AG-09/10 through AG-09/11 and AG-22 are mixed FPR1/FPR2 agonists.
Although AG-09/9 has a quinazolinone backbone, which has been reported to be present in other FPR2 ligands, such as Quin-C1 (Nanamori et al., 2004; Zhou et al., 2007) , the chemotypes present in all other selected agonists have not been reported previously among FPR1/FPR2 ligands.
We found that both selective and non-selective agonists identified in RBL and HL-60 cell assays also induced chemotaxis and Ca 2+ mobilization in human neutrophils, with EC 50 values in the low micromolar or even nanomolar range (Tables 1-4 and Supplemental Table S1 ). As examples, Figure 2 shows representative kinetic curves and dose-response curves for AG-09/1
and AG-09/4, which are FPR1-and FPR2-specific agonists, respectively, in HL-60 cells expressing FPR1 or FPR2 and in human neutrophils.
This article has not been copyedited and formatted. The final version may differ from this version. Figure S1 ). The only outlier was AG-26. Although the reason for this discrepancy is not clear, it is possible that AG-26 may have decreased stability during the longer incubation period needed for the chemotactic assay (60 min vs. 5 min for the Ca 2+ mobilization assay) and could be hydrolyzed or inactivated, resulting in relatively lower chemotactic activity. Further studies are ongoing to evaluate this issue.
Structure-Activity Relationship (SAR) Analysis
Based on structures of the selected compounds, additional analogs were selected and evaluated for FPR1/FPR2 agonist activity in both RBL and HL-60 cells. These analogs included 25 benzimidazol derivatives (designated as AG-09/11 through AG-09/35), which are analogs of FPR1 agonists AG-09/1 and AG-09/2 (Table 2) ; 19 phenylurea derivatives (designated as AG-09/36 through AG-09/54), which are analogs of FPR2 agonist AG-26 (Table 3) (Supplemental Table S1 ). As a result of this secondary screening, 4 novel FPR1-specific agonists, 14 novel FPR2-specific agonists, and 6 compounds with mixed FPR1/FPR2 activity were identified (Tables 2-4 and Supplement Table S1 ). Note that FPR1/FPR2 agonists selected in the primary screening and bearing the relevant scaffolds (AG-09/1, AG-09/2, AG-26, AG-09/3, AG-09/4, and AG-09/7) are included in their respective tables for completeness in SAR analysis.
This article has not been copyedited and formatted. The final version may differ from this version. through AG-09/24) ( Table 2 ). All active derivatives contained either a para methoxy or ethoxy group in the benzene moiety of the benzimidazole cycle, which is an essential feature for activity Table   S1 ). No clear SAR emerged from modification of position R 2 .
As described above, a number of compound analogs had no activity or had low efficacy.
Thus, we considered whether such compounds might be FPR antagonists by pretreating HL-60- Figure S2) . Thus, it appears that these low efficacy agonists may still be able to desensitize cells but are likely not receptor antagonists, since they can directly induce a Ca 2+ flux. Nevertheless, characterization of the mechanisms involved in this inhibition will require further studies.
Pharmacophore Modeling of FPR1/FPR2 Ligand Recognition
Since X-ray structures of FPR1 and FPR2 are not available, it was not possible to use a docking study for modeling the interaction of our agonists with the active sites. However, ligand-based methodologies have been developed to address this issue, such as rapid overlay of chemical structures (ROCS) (Grant et al., 2001; Bologa et al., 2006) . We utilized a ligand-based approach to molecular modeling that uses the field point approach developed by Cheeseright and coworkers (Cheeseright et al., 2006; Cheeseright et al., 2007 ) (see Materials and Methods) . This approach allowed us to compare diverse molecules in terms of their field similarity (Cheeseright et al., 2006) and create an alignment of their bioactive conformations as "seen" by the receptor (Low and Vinter, 2008) . This alignment or template provides an accurate pharmacophore model of an unknown active site (Cheeseright et al., 2006; Cheeseright et al., 2007; Low and Vinter, 2008 (Bürli et al., 2006) and Frohn-11 (Frohn et al., 2007) , and three agonists identified here (AG-09/5, AG-09/74, and AG-26) were selected for development of the FPR2 ligand-binding site template. Using the conformer hunt algorithm (FieldTemplater Version 2.0.1), we generated up to 100 independent conformations lying within 6 kcal/mol energy gap above the lowest-energy geometry for each of the molecules. Field point patterns were calculated for these conformations, and the clique algorithm of FieldTemplater was applied to obtain the best alignment for each group of agonists.
The corresponding multi-molecule templates for FPR1 and FPR2 are shown in Figure 2A and 2B, respectively. Despite high flexibility of the molecules investigated, good alignments are achieved with certain conformations among all conformational pools generated by the program. 
Discussion
FPRs have been implicated in the control of many inflammatory processes, promoting the recruitment and infiltration of phagocytes to sites of inflammation [reviewed in ]. Indeed, targeted disruption of the gene coding for the mouse counterpart of FPR1 rendered mice more susceptible to bacterial infection without significant phenotypic alteration (Gao et al., 1999) , supporting the role of FPRs in innate host defense based on recognition of bacterial-derived agonists. However, the expression pattern of FPRs in non-phagocytic cells, especially that of FPR2, suggests that these receptors participate in functions other than innate immunity and that these receptors may represent unique targets for therapeutic drug design.
FPR2 is activated by numerous and chemically unrelated ligands; however, the responses induced by these ligands acting at the same receptor vary widely and can even oppose each other. For example, annexin 1 accelerates neutrophil apoptosis, whereas serum amyloid A induces an anti-apoptotic signal (El Kebir et al., 2008) . Most of these agonists are chemotactic and elicit proinflammatory responses in human leukocytes; however, lipoxin A 4 is an antiinflammatory agonist and leads to an inhibitory signaling cascade through FPR2 (Serhan, 2007) .
On the other hand, the mechanisms by which different FPR agonists are able to activate a given set of signal transduction pathways and induce a unique array of phagocyte functions still remains a mystery. Clearly, the availability of structurally-defined small-molecule agonists for (Edwards et al., 2005 ) and 1,3-benzodioxolane-5-carboxylic acid hydroxybenzylidene-hydrazide derivatives (compounds AG-14 and AG-104) (Schepetkin et al., 2007; Schepetkin et al., 2008) . Our screening also identified FPR2-specific agonists among the N'-phenylurea derivatives (5 compounds), piperazine derivatives (8 compounds), phenylacetohydrazide derivatives (5 compounds), dibenzoylhydrazine derivatives (AG-09/5), 5-(2-thienyl)-pentanamide derivatives (AG-09/6), and quinazolinone derivatives (AG-09/8).
Importantly, these selected agonists represent several novel chemical scaffolds that have not been reported previously for FPR1 or FPR2 agonists. One exception is the quinazolinone scaffold (backbone for AG-09/8), which has the same backbone scaffold as Quin-C1 (Nanamori et al., 2004; Zhou et al., 2007) . Interestingly, the piperazine scaffold was reported previously to be the backbone scaffold for selective agonists of the dopamine D4 receptor, which is another G protein-coupled receptor (Matulenko et al., 2004) . Whether our specific compounds are also D4 receptor agonists has not been evaluated. Additionally, two compounds with the piperazine scaffold activated Ca 2+ flux in human neutrophils, but did not activate FPR1-or FPR2-This article has not been copyedited and formatted. The final version may differ from this version. transfected cells. Currently, the receptor for these two agonists is unknown. In any case, further development of these novel classes of agonists and analysis of additional derivatives may provide important clues to understanding FPR1/FPR2 structure and function.
FPR1 and FPR2 belong to a receptor family for which X-ray structures of ligand-receptor complexes are not available. Thus, ligand-based approaches can be useful in such cases. Wellknown ligand-based methods, such as comparative molecular field analysis (CoMFA) (Cramer, III et al., 1989) and comparative molecular similarity indices analysis (CoMSIA) (Böhm et al., 1999) , are strongly dependent on the alignment procedure, which gives much better results for structurally related compounds with a common scaffold. On the other hand "scaffold-hopping" using different scaffolds remains a challenging task in drug design. Recently, Cheeseright and coworkers (Cheeseright et al., 2006; Cheeseright et al., 2007) Investigation of a wider series of highly active FPR agonists in the future will bring more information about the significance of these field points.
The pharmacophore models developed here represent ligand-based views of the active sites for FPR1 and FPR2. As such, the spatial arrangement and field point patterns of the molecules in their proposed bioactive conformations does not allow us to deduce an unambiguous correspondence between molecular characteristics and amino acid sequences in homology models of these receptors. Among the notable differences between FPR1 and FPR2 sequences are the following nonconserved changes in FPR2: Arg84Ser, Lys85Met, Arg163Phe, and Asp284Asn. All of these residues have been reported previously to participate in peptide ligand binding (Lala et al., 1999) . Note that each of these changes results in loss of positive charge in the peptide binding pocket. Thus, one could speculate that these changes may lead to a more electronegative binding pocket, which would correspond to the increased number of red (electronegative) field points in FPR2 template compared to the FPR1 template (see Figure 3) .
However, further work is clearly necessary to address the relationship of ligand-based pharmacophore models with specific amino acid sequences identified in homology models.
This article has not been copyedited and formatted. The final version may differ from this version. Recently, Young and coworkers (Young et al., 2009) (Serhan, 2007) . In addition, agonists of FPR1 and FPR2 (i.e., fMLF and MMK-1, respectively) prevented alopecia in neonatal rats induced by the anticancer agent etoposide (Tsuruki et al., 2007) . Furthermore, the ability of FPR2 peptide agonists to up-regulate endogenous tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression has been linked to tumoricidal activity (Lin et al., 2007) . Thus, further development of specific small-molecule FPR agonists represents an important avenue to pursue for therapeutic purposes.
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